On the basis of drug screening data obtained from the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) databases [38, 39], we observed similar results for cell lines with ecMYC and ecDNA containing MYCN that were sensitive to type I AURKi (Fig. 7G and Supplementary Fig. S3F). The gene discussed is MYCN; the disease is cancer.